The KIAA0101 protein is overexpressed in various human cancers, including esophageal cancer (EC). This study assessed the association of KIAA0101 protein with prognosis and resistance to chemotherapy in EC patients and then explored the role of KIAA0101 in EC cells in vitro. A total of 228 EC patients participated in the study. Tissue samples were collected for immunohistochemical analysis of KIAA0101 expression in tumor and normal tissues for association with clinicopathological and survival data. KIAA0101 cDNA or shRNA were transfected into EC cells for assessment of tumor cell viability, sensitivity to cisplatin treatment, and gene expression. Array-based comparative genomic hybridization (aCGH) was used to detect the changed copy-number alterations in cell lines expressing different levels of KIAA0101. Expression of KIAA0101 protein was upregulated in EC tissues, which was associated with pTNM stage, resistance to chemotherapy, tumor recurrence, and poor survival of EC patients. In vitro experiments showed that expression of KIAA0101 enhanced cell proliferation and upregulated cyclins A and B expression, leading to a reduced G1 phase of the cell cycle. KIAA0101 also induced resistance of EC Eca-109 and TE-1 cell lines to cisplatin treatment through a decrease in apoptosis. The aCGH data showed that levels of KIAA0101 expression altered chromosome stability, affecting genes that are associated with cancer progression. In conclusion, upregulated KIAA0101 expression is associated with EC progression, resistance to chemotherapy, and poor survival of the patients.

The present study indicates that elevated preoperative NLR (≥ 5) is a useful marker of tumor recurrence and independently predicts poorer disease-free and overall survival among patients with AEG undergoing R0 resections.

Gastric cancer (GC) is one of the most common malignant tumors with a high rate of recurrence, which results in surgery being unsuccessful. Therefore, it is important to find the reason for the surgery failing. The purpose of the present study was to investigate a factor related to recurrence. Expression of KIAA0101 was assessed in 61 paired human primary GC and non-cancerous gastric tissue using immunohistochemistry. After surgery, all 61 patients were followed regularly for more than 24 months or until death to analyze the 2-year survival rate and recurrence. After suppressing KIAA0101 by RNA interference in human GC cell lines, the cell viability was detected using MTT. We are first to find that KIAA0101 was elevated in GC tissues compared with paired non-cancerous gastric tissues. Immunohistochemical staining also revealed the predominant nuclear localization of KIAA0101 protein. Despite these findings, GC patients with elevated KIAA0101 expression levels exhibited a high recurrence and subsequently poor prognosis in the survival study. Also, cell viability was significantly inhibited after suppressing KIAA0101 in GC cells, suggesting that KIAA0101 might promote cancer cell proliferation. KIAA0101 is increased in human GC and is a marker of recurrence. (Cancer Sci 2013; 104: 353-359) G astric cancer (GC) is one of the most common malignant tumors in the world, yet the prognosis for patients with advanced disease remains very poor.(1-3) Even after surgery, approximately 40-65% of GC patients will experience a recurrence and die from the disease.(4) A variety of clinical and biological variables have been proposed as risk prognostic factors for GC, but the precise molecular mechanisms underlying the development and progression of GC remain unclear. The identification of novel molecular markers for the prediction of recurrence risk in tumor prognosis will contribute to the development of better strategies for patient management.KIAA0101 was first identified as p15 PAF (proliferating cell nuclear antigen [PCNA] associated factor) based on its ability to bind PCNA in a yeast two-hybrid screen in 2001.(5) It is alternatively referred to as L5, (6) OEATC-1 (7) or NS5ATP9.In our earlier study, we used suppression subtractive hybridization (SSH) to show that KIAA0101 was upregulated by hepatitis C virus non-structural protein 5A. (8) We then identified the promoter region of this gene, screened KIAA0101 gene promoter-binding proteins and verified that rhNF-kB could bind to the KIAA0101 promoter and participate in the regulation of KIAA0101 expression.(9) Moreover, recent reports have shown that KIAA0101 can also interact with BRCA1 and regulate centrosome number.(10) Another report demonstrated that KIAA0101 is an APC ⁄ C-regulated protein involved in both cell cycle progression and the DNA damage response. (11) Overexpression of KIAA0101 in mammalian cells was also found to protect cells from UV-induced cell death. (12)(13)(14) Interestingly, Hosokawa et al. (15) found that KIAA0101 had oncogenic activity, as exo...

No abstract

Gamma delta (γδ) T cells can effectively recognize and kill colorectal cancer (CRC) cells, thereby suppressing tumor progression via multiple mechanisms. They also have abilities to exert a protumor effect via secreting interleukin-17 (IL-17). γδ T cells have been selected as potential immunocytes for antitumor treatment because of their significant cytotoxic activity. Immunotherapy is another potential anti-CRC strategy after an operation, chemotherapy, and radiotherapy. γδ T cell-based immunotherapy for CRC shows fewer side effects and better toleration. This review will outline the immune functions and the mechanisms of γδ T cells in the growth and progression of CRC in recent years, and summarize the immunotherapies based on γδ T cells, thus providing a direction for future γδ T cells in CRC research.